Background-Hypertrophic cardiomyopathy caused by mutations in the cardiac troponin T gene (TNNT2) has been associated with a high risk of sudden cardiac death (SCD) and mild left ventricular hypertrophy. However, previous studies are limited by sample size, cross-sectional design, and few data in relatives. Methods and Results-Five hundred fifty-two unrelated hypertrophic cardiomyopathy probands were screened for TNNT2 mutations. First-degree relatives were invited for clinical and genetic evaluation. Ninety-two individuals (20 probands and 72 relatives) carried TNNT2 mutations (51 [55%] male; 30Ϯ17 years). ECGs and echo were available in 87 (95%) and 88 (96%) individuals, respectively. ECG was normal in 13 (68%) children (Ͻ16 years) and 13 (19%) adults. Echo was normal in 18 (90%) children and 16 (24%) adults; 7 (10%) adults had a normal ECG and echo. Thirteen (65%) of 20 families had a history of SCD. Follow-up was available for 75 patients (mean, 9.9Ϯ5.2 years); 2 of 16 adults and 2 of 18 children with normal echoes developed left ventricular hypertrophy. Twenty-three (22%) received an implantable cardioverter-defibrillator (20 for primary prophylaxis). One child and 3 adults died of SCD and 2 adults were resuscitated from ventricular fibrillation. One patient had an appropriate implantable cardioverter-defibrillator discharge. The rate of cardiovascular death, transplant, and implantable cardioverter-defibrillator discharge was 1.6% (0.016 person/y; 95% confidence interval, 0.83-2.79%), and SCD 0.93% (0.0093 person/y; 95% confidence interval, 0.37-1.92%). Conclusions-Left ventricular hypertrophy is rare in children with TNNT2 mutations. Left ventricular hypertrophy is absent in the minority of adults, but most have an abnormal ECG. Despite adverse family histories, the rate of cardiovascular death during follow-up was similar to that reported in large referral populations. (Circ Cardiovasc Genet. 2012;5:10-17.) (J.M.). The online-only Data Supplement is available at http://circgenetics.ahajournals.org/lookup/suppl/
H ypertrophic cardiomyopathy (HCM), defined as left ventricular hypertrophy (LVH) in the absence of abnormal loading conditions, occurs in approximately 1 in every 500 adults. 1 The disease can present with cardiovascular symptoms at any age and is a frequent cause of sudden cardiac death in young people. [2] [3] [4] In the long term, many patients develop progressive symptoms caused by a gradual deterioration in left ventricular function. 5, 6 Clinical Perspective on p 17 HCM is usually inherited as an autosomal dominant trait caused by mutations in genes that encode proteins of the cardiac sarcomere. [7] [8] [9] [10] Based on the assumption that locus and allelic heterogeneity have different effects on myocyte structure and function, it has been hypothesized that individual mutations are associated with specific phenotypes. 10 -15 If this is correct, then mutation analysis could be used to guide therapy (eg, prophylactic implantation of implantable cardioverter-defibrillators) and counseling strategies for families. One of the first reported genotype-phenotype associations in HCM was a high prevalence of sudden cardiac death in young carriers of mutations in the cardiac troponin T gene (TNNT2), 9,16 -18 paradoxically in the presence of only mild left ventricular hypertrophy. 19, 20 Although this finding has been used in subsequent consensus management guidelines for HCM, studies examining the natural history of troponin T gene mutations are limited by the small size of patient cohorts (often single families), cross-sectional study design, and a lack of data on disease expression in relatives. The aim of this study was to examine clinical outcomes in a relatively large cohort of patients and relatives with mutations in the cardiac troponin T gene.
Kingdom. All study participants gave written informed consent for venesection and DNA analysis. The study conformed to the principles of the Helsinki declaration. All authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the manuscript as written.
Clinical Evaluation
The study cohort comprised apparently unrelated HCM probands referred to a dedicated cardiomyopathy clinic over a 10-year period to St George's Hospital and then subsequently followed (2003) (2004) (2005) at The Heart Hospital, UCLH, London, United Kingdom, who were tested for mutations in the TNNT2 gene. All relatives of mutation positive individuals were invited for clinical and genetic evaluation.
Patients and consenting relatives underwent supine 12-lead ECG, M-mode, 2D, and Doppler echocardiography, symptom-limited upright exercise testing with simultaneous respiratory gas analysis, and 24 -48-hour ambulatory ECG monitoring in accordance with previously described methods. 21 LVH on the 12-lead ECG was defined using the Romhilt-Estes score system 22 ; LVH was defined as a score Ն5. ECGs in infants and children were reviewed by a pediatric cardiologist (Dr Kaski) and were coded using standard criteria. 23 HCM was diagnosed in probands and relatives when the maximum left ventricular wall thickness (MLVWT) measured Ն13 mm in Ն1 myocardial segments on echocardiography or when left MLVWT exceeded 2 standard deviations corrected for age, size, and sex in the absence of other diseases that could explain the hypertrophy. 24 The pattern of hypertrophy was classified as asymmetrical septal, concentric, or predominantly apical. 25 In probands with sudden death as the first clinical manifestation, the diagnosis of HCM was, when possible, confirmed at postmortem examination. Relatives were considered clinically affected when they fulfilled extended familial criteria for HCM. 26 During ambulatory monitoring, supraventricular tachycardia was defined as Ն3 consecutive supraventricular premature beats at a rate Ͼ100 bpm and nonsustained ventricular tachycardia (NSVT) as Ն3 consecutive ventricular ectopics at a rate Ͼ120 bpm. An abnormal blood-pressure response during symptom limited upright exercise testing was defined as a failure of systolic blood pressure to rise by Ͼ25 mm Hg from baseline values or a fall of Ͼ10 mm Hg from the maximum blood pressure during upright exercise. 27 
Clinical Risk Stratification
Risk stratification was considered complete when patients had at least 1 echocardiogram, ambulatory ECG recording, and exercise test. Major risk factors for sudden cardiac death were defined as: a family history of sudden cardiac death at an age Յ40 years; a syncopal episode suggestive of arrhythmic origin; NSVT during ambulatory electrocardiography; MLVWT Ն30 mm; and an abnormal exercise blood pressure response. 28 
Genetic Evaluation
Genomic DNA was extracted from whole blood and protein encoding exons of TNNT2 were amplified using standard protocols (primer sequences and conditions for polymerase chain reaction amplification are available on request). Mutation analysis of TNNT2 was performed by fluorescent SSCP (F-SSCP) and direct sequencing of abnormal conformers. As reported previously, the sensitivity of F-SSCP to identify sequence variations in TNNT2 was 100%. 29, 30 DNA was screened for mutations in TNNT2 hot spot exons 8, 9, and 16 . If these did not show mutations, exons 10, 11, 13, 14, and 15 were also screened. When no mutation was identified, the TNNT2 gene was completely sequenced. When a disease causing mutation was found in TNNT2, genetic analysis was interrupted.
A cohort of 200 healthy white volunteers served as control subjects for TNNT2 sequence variants reported in this study. A sequence variant was defined as a pathogenic mutation if it was absent in a cohort of 400 control chromosomes; it was predicted to result in a premature truncation, frameshift, or abnormal splicing or affected conserved amino acid residues and cosegregated with disease in the family (when information was available). Variants previously reported as mutations were considered disease causing unless we could show otherwise. The likelihood of pathogenic effect of all TNNT2 sequence variants was determined by in silico prediction methods: PolyPhen-2 and SIFT for missense mutations and splice site prediction software Neural Network and Genio/splice.
Statistics
SPSS (v 13.0) was used for all statistical analyses. Normally distributed data are expressed as mean (95% confidence intervals [CI]). Differences between means were compared using the unpaired 2-tailed Student t test. The 2 test was used for comparison of categorical data. The Mann-Whitney U test was used to analyze nonnormally distributed continuous data.
The predefined end points in the survival analysis were: sudden cardiac death (witnessed death with or without documented ventricular fibrillation, death within 1 hour of new symptoms, or nocturnal deaths with no antecedent history of worsening symptoms); first appropriate implantable cardioverter-defibrillator (ICD) shock; heart failure death (death preceded by signs and/or symptoms of heart failure, including cardiogenic shock); orthotopic heart transplantation; and other cardiovascular death (stroke, pulmonary or peripheral arterial embolization, procedure-related and myocardial infarction). Deaths of unknown cause were classified as noncardiovascular deaths.
The cumulative probability for the occurrence of an outcome was estimated using the Kaplan-Meier method. Survival from cardiovascular death, cardiac transplant, and appropriate ICD shock was modeled for all probands and relatives with an identified mutation in the TNNT2 gene from their first evaluation at our institution.
To facilitate comparison with previously published data, survival was also modeled from birth incorporating additional data on relatives (alive and dead) identified from pedigree analysis that were known to have HCM (in life or at autopsy) or were obligate carriers of a TNNT2 mutation. Analysis of survival from birth was also performed for individual mutations.
A probability value Ͻ0.05 was considered significant in all analyses.
Results

Genetic Investigations
Five hundred and fifty-two probands were screened for TNNT2 mutations. Twenty (3.6%) had pathogenic mutations. Two hundred thirty-six relatives consented to clinical and genetic testing; of these, 72 (30.5%) had a mutation. Ethnicity data were confirmed in 18 of the 20 families with TNNT2 mutations: 1 family of Indian ethnicity; 1 Caribbean; 1 Pakistani, and the remaining 15 families white British.
Twelve different mutations in exons 8, 9, 11, 15 , and 16 were identified in 20 families: Arg278Cys in 3 families; Arg92Leu in 2 families; Arg92Trp in 3 families; ⌬Glu163 in 3 families; IVS15ϩ1GϾA in 2 families; and Ala104Val, Arg278His, Arg92Gln, Arg94Leu, Glu163Lys, Glu83Lys, Ile79Asn in single families. Of the 12 sequence variants in this study, 11 have already been reported (online-only Data Supplement Table I) as disease-causing in HCM. 9, 16, 18, 20, 29, 31, 32 A summary of the bioinformatics analysis of the missense mutations (ie, 9 known and 1 novel) is provided as a supplemental data file (online-only Data Supplement Table II) .
Analysis of the IVS15ϩ1GϾA mutation by splice site prediction software (Neural Network and Genio/splice) showed that this sequence change completely abolishes the splice donor site of exon 15 of TNNT2 and is predicted to result in abnormal splicing of the troponin T protein.
The Arg278His sequence variant has not been reported before and was considered pathogenic on the basis of definition described in the Methods section.
Clinical Investigations
The ECG and echocardiogram at first evaluation were available for review in 87 (95%) and 88 (96%) of the 92 mutation carriers. At least 1 ambulatory ECG recording was available in 68 (74%) patients.
The ECG characteristics of adult and pediatric mutation carriers are shown in Table 1 . Thirteen adults and 13 children had a normal ECG. In the pediatric population, the echo was normal in 18 individuals (90%). Two children aged 14 and 15 years had an abnormal echo with asymmetrical septal hypertrophy (ASH) and concentric hypertrophy, respectively; the ECG was abnormal in both children. In adults, the echo was normal in 16 individuals (24%). The echo features of the adult population are shown in Table 2 . The relation between echo and ECG findings in adults are shown in Figure 1 . The relation between age and echo findings at initial evaluation is shown in Figure 2 .
Risk stratification at the initial clinical evaluation was complete for 54 (76%) adults and 10 (47%) children (Table  3) . A history of sudden cardiac death at any age was present in 13 (65%) of the 20 families analyzed. Eight of these 20 families (40%) had a family history of multiple sudden cardiac deaths; in 5 families (25%) there was only 1 sudden cardiac death.
Pedigree Analysis
In addition to the 92 proven carriers of a TNNT2 mutation, 29 cases of sudden cardiac death were identified from pedigree analysis. Of these, 5 (age of death: 17, 21, 26, 22, and 51 years) had a postmortem report consistent with HCM; 5 (age of death: 38, 42, 59, 53, and 50 years) were obligate carriers of a mutation; and 2 were known to be affected with HCM before death but were followed at other centers. A further 17 relatives (mean age, 24 years; range, 5-59 years) died suddenly in circumstances suggesting a cardiac origin, but because the diagnosis of HCM could not be confirmed, they were excluded from further analysis.
Changes in Echocardiographic Parameters During Follow-Up
Follow-up echoes were available in 45 adults and 14 children (mean intervals between echoes, 9.3Ϯ5 years and 6.9Ϯ2.9 years, respectively). There were no significant changes in mean cardiac dimensions or systolic function, but 3 patients (MLVWT: 23 Follow-up echoes were available in 11 of 16 adults with a normal echo at presentation (interval between echoes, 8.7Ϯ5.2 years; range, 1-18 years). Two had hypertrophy: one with a normal echo at 27 years had concentric hypertrophy with a maximal wall thickness of 17 mm when 42 years old; the second had a normal echo (MLVWT: 9 mm), aged 65, and ASH (13 mm) by the age of 74 years.
Thirteen of the 18 children with normal echoes at first evaluation had follow-up echoes (range, 4 -15 years; mean, 6.7Ϯ3 years): 2 had asymmetrical left ventricular hypertrophy at the age of 19 and 29 years, respectively.
Events During Follow-Up
Clinical follow-up was available for 75 patients (81%; mean, 9.9Ϯ5.2 years). The duration of follow-up in adults (nϭ57) was 10.3Ϯ5.4 years and in children (nϭ18) 8.2Ϯ3.5 years.
Twenty-three individuals (22%) received an ICD: 20 for primary prophylaxis; 2 for secondary prophylaxis; and 1 biventricular device for congestive cardiac failure. Three persons received a dual-chamber pacemaker for AV nodal disease and 1 for left ventricular outflow tract obstruction. One individual underwent radiofrequency ablation for atrial fibrillation and later required atrioventricular node ablation and biventricular pacemaker insertion. One individual underwent septal myomyectomy for left ventricular outflow tract obstruction.
Three adults died of sudden cardiac death and 2 were resuscitated from ventricular fibrillation (VF); of these, 3 (age at death or VF: 20, 29, and 63 years) were men of Indian ethnicity from the same family with the Arg92Gln mutation. The maximal wall thickness in these individuals was 27 mm, 15 mm, and 20 mm, respectively. The third sudden death occurred in a female carrier of Glu163del, aged 62 years, with NSVT, a family history of multiple sudden deaths, and MVLWT 18 mm. No postmortem data were available. One woman carrying the Arg278Cys mutation was resuscitated from VF arrest at age 26. At that time, she had a concentric hypertrophy and the maximal wall thickness was 23 mm. She is still alive 18 years later but has left ventricular dilation and impaired left ventricular systolic function. She has a monozygotic twin who had an ICD implanted for primary prophylaxis, but during follow-up she did not receive any ICD therapies.
Of the remaining adults, 1 (MLVWT, 23 mm) received an appropriate ICD shock for symptomatic VT (IVS15ϩ1GϾA) and 4 (Glu163del; Arg94Cys; Arg278Cys; IVS15ϩ1GϾA) died of heart failure at ages 29, 65, 65, and 68 years. In the pediatric cohort, 1 patient with the Ile79Asn mutation died suddenly at age 16 with no echo features of HCM (maximal wall thickness was 9 mm); his cousin died of complications during an ICD lead extraction at another center.
Kaplan-Meier survival curves for the study population are shown in Figure 3A and 3B. When modeled from the time of first evaluation at our institution, (including 2 individuals who presented with cardiac arrest as a first event), the annual rate of cardiovascular death, transplant, and ICD discharge in probands and relatives with a TNNT2 mutation was 1.6% (0.016 person/y; 95% CI, 0.83-2.79%) and the rate of sudden cardiac death 0.93% (0.0093 person/y; 95% CI, 0.37-1.92%).
When survival was modeled from birth for definite TNNT2 carriers and additional relatives identified from pedigree analysis that were known to have HCM or were obligate gene carriers the annual rate of cardiovascular death, transplant, and ICD discharge was 0.64% (0.0064 person/y; 95% CI, 0.41-0.96%) and the rate of sudden cardiac death 0.51% (0.0051 person/y; 95% CI, 0.31-0.79%). Figure 4 shows survival from birth for individual mutations. Two mutations (Ile79Asn and Arg92Gln on exon 8 and 9, respectively) appeared to be associated with a higher rate of sudden death at a juvenile age, at least in comparison with IVS15ϩ1 GϾA and Glu163del mutations. The small number of sudden cardiac deaths (nϭ7) means that it is very difficult to perform subgroup analyses (online-only Data Supplement III). However, in comparing probands with relatives, there was no difference in cardiac mortality (Kaplan-Meier logrank test Pϭ0.62). Similarly, there was no difference in cardiac mortality in patients with echocardiographic expression of disease versus carriers without LVH (Kaplan-Meier log-rank test: Pϭ0.21).
Discussion
This is the largest study of patients with mutations in the TNNT2 gene since the first clinical report suggesting that this form of hypertrophic cardiomyopathy is characterized by a high incidence of sudden cardiac death. 16 The findings confirm that a history of young sudden cardiac death is common in many families and that mild or absent hypertrophy is present in a minority of adult mutation carriers.
Disease Penetrance
In common with most other reports, this study shows that disease penetrance (defined by echocardiographic evidence for HCM) is low in children. A substantial minority of adults with TNNT2 mutations also have normal echoes, although most of these had an abnormal ECG, emphasizing the role of both tests in clinical screening. In those adults with an abnormal echo, the distribution and severity of myocardial hypertrophy was very similar to that reported in other sarcomere protein mutations. 33 The one major difference with larger studies was a lower prevalence of left ventricular outflow tract obstruction, which was present in less than 10% of patients. The reasons for this are not clear from this study, but we cannot exclude the possibility that some individuals had provocable obstruction.
Survival Analyses
A recent meta-analysis of large cohort studies indicates that the rate of sudden death in patients fulfilling diagnostic criteria for HCM is Ͻ1% per annum. 34 However, prospective data on outcomes in genotyped patients are scarce and studies rarely consider both probands and relatives that carry the same mutation.
In the case of TNNT2, we identified 5 studies that have reported on survival. 16, 18, 32, 35, 36 Overall, 166 carriers of TNNT2 mutations identified by genetic and pedigree analysis are reported. Of these, 61 died of an apparent cardiac cause, the majority (nϭ50) of whom died suddenly. In 2 studies, however, the number of sudden deaths was low, in accord with the prospective data in this report (Table 4) .
Although we adopted a conservative approach to the coding of deaths in relatives, pedigree analysis still demonstrated a high prevalence of sudden cardiac death in affected families. However, when we examined survival in the prospectively followed cohort, the annual rate of sudden death was Ͻ1% and in line with the average seen in large follow-up studies. 34 One possible explanation for this apparent paradox is the use of prophylactic ICDs in patients and relatives deemed to be at high risk, but this seems unlikely, given that only a single patient (of 23 with a device) had an appropriate ICD therapy for sustained ventricular arrhythmia during follow-up. Another possibility is the inclusion of relatives with a mild or absent clinical phenotype, which could have resulted in better outcomes. This study was too small to conduct adequately powered subgroup analyses, but the annual rate of sudden death was similar in probands and relatives suggesting that other mechanisms including genetic, epigenetic, and environmental factors were at least partially responsible for the better outcomes in individuals with a phenotype.
A number of studies have reported sudden deaths in TNNT2 mutation carriers with little or no hypertrophy. The same phenomenon was seen in a few patients in this study, but the relative paucity of events in the prospectively fol- lowed cohort means that we cannot determine the relative risk of sudden death in mutation carriers with normal echoes. Similarly, although most deaths occurred in families with mutations in exons 8 and 9, this study was not powered to detect differences in outcome between specific mutations.
Comparison With Other Sarcomere Protein Gene Mutations
A lack of prospective survival data in patients with other sarcomere protein gene mutations makes direct comparison with this study challenging. A recent study 37 evaluating not only probands but also asymptomatic relatives carrying MyBPC3 mutations (a total of 235 mutations carriers) reported an annual rate of sudden cardiac death of only 0.1%. However, approximately two-thirds of the population carried a well recognized Dutch founder mutation, limiting comparison with our own population in which there was a greater spectrum of genetic abnormalities including single base substitutions, deletions and splice-donor site mutations.
Disease Progression
Progressive myocardial thinning and contractile impairment is a well-recognized phenomenon in HCM. 5, 6 In this study, the rate of disease progression appeared slow in that only 3 patients had ventricular dilatation after more than a decade of follow-up. However, 5 patients already had ventricular dilatation at presentation (age, 48 -64 years) and 4 patients died of heart failure during follow-up, suggesting that progression to heart failure may be relatively common in patients with TNNT2 mutations.
Limitations
The population in this study is inevitably subject to referral and ascertainment bias. The selection of the population is also different from some previous reports in that we included only patients with genetic, clinical, or pathological confirmation of the disease, whereas in previous outcome studies all relatives who died suddenly were presumed affected with disease. This means that the burden of sudden death caused by TNNT2 mutations may have been underestimated in some families. The extreme phenotypic variability observed in this study shows that outcomes in individuals carrying mutations in TNNT2 is influenced by many factors other than the position and nature of the mutation itself. Because of financial and other inevitable constraints in a study performed over 2 decades, we were unable to exclude the possibility that some patients harbored additional sarcomere protein gene mutations. However, contemporary genetic studies indicate that this occurs in only 5% of patients. 38 Although double mutations could account for a high mortality in individual families, it is unlikely that the presence of additional mutations explains for the relatively low annual incidence of sudden death observed in the prospective cohort.
Conclusion
Investigation of genotype-phenotype relations in a diverse and complex disorder such as HCM is challenging. Although this study shares many of the limitations of previous studies, it is reasonable to conclude the following about TNNT2 mutations: ventricular hypertrophy is uncommon in children and adolescents; ventricular hypertrophy on echo is absent in an important minority of adult patients; irrespective of echocardiographic findings, most adult carriers have an abnormal ECG; sudden cardiac death is an important complication, but at least in this prospectively managed cohort, its incidence is no greater than in most contemporary cohort studies; and finally, although rare, sudden cardiac death can occur in individuals with little or no hypertrophy. 
